康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

未开盘 10-28 16:08:25

85.050

+4.200

+5.19%

最高86.300	最低82.500	成交量1,057万
今开82.600	昨收80.850	日振幅4.70%
总市值800.32亿	流通市值800.32亿	总股本9.41亿
成交额8.95亿	换手率1.12%	流通股本9.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":85.05,"timestamp":1793174905007,"preClose":80.85,"halted":0,"volume":10566722,"delay":0,"changeRate":0.051948051948051986,"floatShares":941000000,"shares":941000000,"eps":-1.4514555208491877,"marketStatus":"未开盘","change":4.2,"latestTime":"10-28 16:08:25","open":82.6,"high":86.3,"low":82.5,"amount":895339653,"amplitude":0.047001,"askPrice":85.1,"askSize":1000,"bidPrice":85.05,"bidSize":11000,"shortable":3,"etf":0,"ttmEps":-1.2450644753693232,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793237400000},"marketStatusCode":0,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":80.85,"openAndCloseTimeList":[[1793151000000,1793160000000],[1793163600000,1793174400000]],"volumeRatio":0.818707,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.7251,"impliedVolPercentile":0.8953},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"2678459668","title":"里昂：中国医疗健康板块近期回调属买入机会 海外及内地趋势改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2678459668","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678459668?lang=zh_cn&edition=full","pubTime":"2026-10-28 16:03","pubTimestamp":1793174593,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，里昂发布研报称，中国医疗健康板块近期回调主要受宏观忧虑推动，相关因素大致已反映于股价;海外进展及内地营运持续改善，宏观环境亦已企稳，该行视近期回调为买入机会。于ESMO 2026，中国资产占96项LBA中的29项，以及12场Presidential Symposium中的5场。该行维持中国医疗健康股票篮子不变，指医疗健康占基金总持仓不足2%，估值折让提供更具吸引力的长线买入机会;进一步海外临床进展及新的III期资产BD交易亦应为板块提供支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348766576.USD","LU2097828805.USD","09887","IE00B031HY20.USD","LU0607220059.USD","IE0008369823.USD","VHT","XBI","LU1813983027.USD","KURE","159760","LU2399975544.HKD","LU1008478684.HKD","LU1328277881.USD","LU2328871848.SGD","XLV","IE00BPRC5H50.USD","01801","02595","LU2476274720.SGD","LU0501845795.SGD","LU1226287875.USD","LU0561508036.HKD","IE00B5MMRT66.SGD","BK1589","LU1993786604.SGD","01093","09926","LU1226288253.USD","LU0417516738.SGD","IE00BZ08YS42.EUR","BK1583","BK4581","LU0326950275.SGD","LU1226288170.HKD","BK1521","BK4550","LU0348783233.USD","LU2488822045.USD","BK1191","LU0417516902.SGD","LU0196878994.USD","LU2097828631.EUR","BK1574","LABU","LU1969619763.USD","LU0417516571.SGD","06990","BK4588","IXJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678437565","title":"港股异动 | 康方生物(09926)涨超5% HARMONi-GI1研究结果在2026 ESMO大会重磅发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2678437565","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678437565?lang=zh_cn&edition=full","pubTime":"2026-10-28 13:57","pubTimestamp":1793167048,"startTime":"0","endTime":"0","summary":"消息面上，近日，康方生物发布公告，HARMONi-GI1/AK112–309作为Late-Breaking Abstract 入选2026 ESMO大会主席论坛口头报告，由主要研究者、复旦大学附属中山医院院长周俭院士报告。据悉，HARMONi-GI1/AK112–309是一项评估依沃西联合化疗对比度伐利尤联合化疗一线治疗晚期胆道癌的随机、对照、双盲、注册性III期临床研究，共入组682例受试者。HARMONi-GI1研究的突破性数据，有力地支持了依沃西联合化疗作为晚期胆道癌一线治疗的新标准疗法的潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1514030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KURE","09926","LU1961090484.USD","LU0348784397.USD","LU1720050803.USD","IE00B5MMRT66.SGD","LU2778985437.USD","BK4585","LU0540923850.HKD","BK1574","VXUS","LU2399975544.HKD","LU0561508036.HKD","LU0348766576.USD","LU0348827113.USD","BK1161","IE00B543WZ88.USD","LU0348783233.USD","LU2488822045.USD","IE00BPRC5H50.USD","LU0348735423.USD","LU2476274308.USD","LU2476274720.SGD","BK4588","LU1794554557.SGD","KCAI","LU0417516571.SGD","LU0348767384.USD","LU0634319403.HKD","LU0417516902.SGD","LU0348825331.USD","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678243653","title":"创新药概念板块走强 恒瑞医药（01276）涨超11% 券商看好ADC、双抗等出海赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2678243653","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678243653?lang=zh_cn&edition=full","pubTime":"2026-10-28 10:32","pubTimestamp":1793154754,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念板块走强，截至发稿，恒瑞医药 涨11.14%，金斯瑞生物涨9.39%，康方生物涨4.70%，诺诚健华涨3.50%，欧康维视生物-B涨3.33%，亚盛医药涨2.65%，翰森制药涨2.32%。2026年，继续看好中国创新药出海的产业趋势，继续重点跟踪ADC、双抗、小核酸、减肥药等核心优势赛道的投资机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994616","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","LU0348783233.USD","HK0000320264.USD","LU2097828474.EUR","BK1589","LU2778985437.USD","BK0183","03692","BK1583","BK1191","LU0634319403.HKD","IE00B543WZ88.USD","LU2476274720.SGD","06855","01276","01548","IE00B5MMRT66.SGD","KURE","LNGR","LU1064130708.USD","600276","MEDX","LU1328615791.USD","LU1997245177.USD","LU0348827113.USD","LU1961090484.USD","LU0417516902.SGD","IBBQ","LU0348735423.USD","LU1781817850.SGD","BK0188","LU2328871848.SGD","09926","LU0405327148.USD","LU2289578879.USD","LU0359201612.USD","LU0417516738.SGD","LU1720050803.USD","BK1161","KCE","06978","09969","LU0359201885.HKD","LU1820825898.SGD","01477","LU0417516571.SGD","LU1655091616.SGD","LU0348767384.USD","159992","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678543311","title":"【券商聚焦】交银国际维持康方生物（09926）买入评级 料依沃西多瘤种全球开发有望持续提升其价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2678543311","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678543311?lang=zh_cn&edition=full","pubTime":"2026-10-28 09:36","pubTimestamp":1793151392,"startTime":"0","endTime":"0","summary":"该机构认为依沃西多瘤种全球开发有望持续提升其价值。维持买入评级和175港元目标价。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994606","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107666705","title":"异动解读｜康方生物盘中上涨3.65%，ESMO重磅数据与优先审评预期提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1107666705","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107666705?lang=zh_cn&edition=full","pubTime":"2026-10-28 09:34","pubTimestamp":1793151288,"startTime":"0","endTime":"0","summary":"10月28日，康方生物盘中上涨3.65%，报84.0港元，成交额1.04亿港元。消息面上，公司此前披露依沃西一线治疗晚期胆道癌III期研究HARMONi-GI1取得阳性结果，并入选ESMO主席论坛口头报告，相关适应症此前亦被拟纳入优先审评。该研究为随机、对照、双盲、注册性III期临床，共入组682例受试者。公司表示，截至目前依沃西已开展超过60项II/III期临床研究，其中18项为全球范围III期研究，强化了市场对其核心管线临床与商业化前景的关注。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康方生物盘中上涨，ESMO重磅数据引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678140953","title":"医药股走低 恒生生物科技指数跌2.48% 映恩生物-B（09606）大跌31.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678140953","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678140953?lang=zh_cn&edition=full","pubTime":"2026-10-27 14:18","pubTimestamp":1793081937,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股走低，恒生生物科技指数大幅跌2.48%。成分股中，映恩生物-B跌31.05%，亚盛医药跌6.70%，科伦博泰生物跌5.96%，三生制药跌5.10%，石药集团跌4.25%，康方生物跌3.63%，中国生物制药跌3.26%，翰森制药跌3.10%，百济神州跌3.03%。近两个月连锁药房密集推出股权激励，驱动板块逻辑从“政策博弈”转向“业绩锚定”。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MDc3ODQ0ZjRmZjY3NDY3NWE2ZmExZWEzMjkyYmRjMmI4NjI3MTMyNDA2NzU1.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994559","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008369823.USD","LU0417516902.SGD","LU0501845795.SGD","LU0561508036.HKD","LU0634319403.HKD","09606","LU1993786604.SGD","LU0140636845.USD","01530","KURE","IE00BZ08YR35.GBP","LU1328277881.USD","03692","09926","LU0348827113.USD","HK0000252152.HKD","06160","LU0315179316.USD","LU2488822045.USD","09939","01093","159938","SG9999004220.SGD","LU1226287792.SGD","LU0314109678.HKD","01177","IE0008368742.USD","LU1719994722.HKD","BK1588","LU2476274720.SGD","LU2039709279.SGD","LU0880133367.SGD","LU1226287875.USD","BK1515","06855","BK1593","LU1961090484.USD","HK0000500386.USD","LU0348783233.USD","LU1226288253.USD","LU1226287529.USD","LU1969619763.USD","LU0588546209.SGD","LU0348784397.USD","06990","BK1583","LU0417516738.SGD","LU0348766576.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116324659","title":"异动解读｜康方生物盘中下跌3.03%，ESMO重磅数据落地后股价仍承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1116324659","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116324659?lang=zh_cn&edition=full","pubTime":"2026-10-27 09:48","pubTimestamp":1793065735,"startTime":"0","endTime":"0","summary":"10月27日，康方生物盘中下跌3.03%，报81.55港元，成交额1.78亿港元。消息面上，公司披露依沃西一线治疗晚期胆道癌III期研究HARMONi-GI1取得阳性结果，并入选ESMO主席论坛口头报告。该研究为随机、对照、双盲、注册性III期临床，共入组682例受试者，相关适应症此前已被拟纳入优先审评。康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康方生物盘中下跌，ESMO重磅数据落地仍承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192197394","title":"异动解读｜康方生物盘中下跌3.12%，ESMO重磅数据落地后股价仍承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1192197394","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192197394?lang=zh_cn&edition=full","pubTime":"2026-10-26 09:53","pubTimestamp":1792979613,"startTime":"0","endTime":"0","summary":"10月26日，康方生物盘中下跌3.12%，报83.9港元，成交额1.6亿港元。消息面上，公司披露依沃西一线治疗晚期胆道癌III期研究HARMONi-GI1取得阳性结果，并入选ESMO主席论坛进行口头报告。该研究为随机、对照、双盲、注册性III期临床，共入组682例受试者，相关适应症此前已被拟纳入优先审评。不过，公司近期刚完成2000万股新股配售，净募资约19.41亿港元，摊薄与融资后的交易压力仍在消化，令利好消息未能立即转化为股价表现。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康方生物异动下跌，ESMO重磅数据落地仍承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145331052","title":"康方生物（09926）披露依沃西一线治疗晚期胆道癌III期研究阳性结果，2026年ESMO主席论坛口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1145331052","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145331052?lang=zh_cn&edition=full","pubTime":"2026-10-26 07:45","pubTimestamp":1792971954,"startTime":"0","endTime":"0","summary":"2026年10月26日，康方生物科技（开曼）有限公司发布自愿公告称，其III期临床研究HARMONi-GI1 / AK112-309被选为2026年欧洲肿瘤内科学会大会主席论坛Late-Breaking Abstract，并将由主要研究者、复旦大学附属中山医院院长周俭院士进行口头报告。截至目前，依沃西已开展超过60项II/III期临床研究，其中18项为全球范围III期研究。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678913449","title":"康方生物(09926)：依沃西联合化疗对比度伐利尤联合化疗一线治疗晚期胆道癌 HARMONi-GI1研究结果在2026 ESMO重磅发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2678913449","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678913449?lang=zh_cn&edition=full","pubTime":"2026-10-26 07:44","pubTimestamp":1792971866,"startTime":"0","endTime":"0","summary":"HARMONi-GI1/AK112–309是一项评估依沃西联合化疗对比度伐利尤联合化疗一线治疗晚期胆道癌的随机、对照、双盲、注册性III期临床研究，共入组682例受试者。目前依沃西联合化疗一线治疗胆道癌已被国家药品监督管理局拟授予优先审评资质。此外，依沃西海外合作伙伴Summit Therapeutics已与美国ECOG-ACRIN癌症研究组达成合作，已启动依沃西联合化疗对比帕博利珠单抗或度伐利尤单抗联合化疗一线治疗晚期胆道癌的全球多中心注册性II/III期临床EA2251研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","LU0348784397.USD","IE00BPRC5H50.USD","LU2488822045.USD","LU2778985437.USD","LU0348783233.USD","LU0417516738.SGD","LU0348825331.USD","LU2476274720.SGD","LU2476274308.USD","BK1161","LU0540923850.HKD","LU0417516902.SGD","09926","LU0417516571.SGD","LU0348767384.USD","LU1720050803.USD","IE00B543WZ88.USD","KURE","IE00B5MMRT66.SGD","LU0561508036.HKD","LU1961090484.USD","LU0348766576.USD","LU1794554557.SGD","LU0348735423.USD","LU0348827113.USD","LU2399975544.HKD","LU0634319403.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678139784","title":"银华基金马君旗下港股创新药ETF银华三季报最新持仓，重仓康方生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2678139784","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678139784?lang=zh_cn&edition=full","pubTime":"2026-10-26 05:25","pubTimestamp":1792963528,"startTime":"0","endTime":"0","summary":"证券之星消息，10月26日银华基金旗下马君管理的银华国证港股通创新药交易型开放式指数基金公布三季报，近1年净值增长率-21.62%。并对康方生物增仓84.5万股，为该基金第一大重仓股；详细数据如下：本文数据来源于港股创新药ETF银华三季报，仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600001362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09926","LU0348825331.USD","LU0634319403.HKD","LU1961090484.USD","LU0348827113.USD","LU0540923850.HKD","LU2488822045.USD","IE00BPRC5H50.USD","LU0348766576.USD","LU0417516571.SGD","159316","LU0348735423.USD","LU0561508036.HKD","KURE","LU2399975544.HKD","LU1794554557.SGD","LU2476274308.USD","LU2476274720.SGD","IE00B543WZ88.USD","LU2778985437.USD","LU0348767384.USD","LU0417516902.SGD","IE00B5MMRT66.SGD","LU0348784397.USD","LU0417516738.SGD","LU1720050803.USD","BK1161","LU0348783233.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186906284","title":"康方生物依沃西单抗新适应症拟纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1186906284","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186906284?lang=zh_cn&edition=full","pubTime":"2026-10-23 20:28","pubTimestamp":1792758483,"startTime":"0","endTime":"0","summary":"10 月 23 日，CDE 官网公示，康方生物依沃西单抗注射液的一项新适应症拟纳入优先审评，适应症为依沃西单抗联合化疗用于局部晚期或转移性胆道癌的一线治疗。在中国，依沃西已经获批三项适应症，适应症包括 EGFR-TKI 耐药的 nsq-NSCLC、一线治疗 PD-L1 阳性 NSCLC、一线治疗鳞状 NSCLC。2022 年 12 月，康方生物以 50 亿美金+2 位数百分比销售提成的方案，将依沃西部分海外权益许可给美国 Summit 公司。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s?__biz=MzAxNjI5NzI4MA==&mid=2247577674&idx=6&sn=62e88856cf9dfa1b649498ba86e8d2b8&chksm=9a94873dff1496b77fdceafbf7d19cd746c9f33586b3833eb0bd1028286a548a3940005fa3fe&scene=27","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1792758509289","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677481109","title":"ESMO年会开幕，创新药快速拉升，恒生生物科技指数翻红","url":"https://stock-news.laohu8.com/highlight/detail?id=2677481109","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677481109?lang=zh_cn&edition=full","pubTime":"2026-10-23 13:56","pubTimestamp":1792734960,"startTime":"0","endTime":"0","summary":"10月23日午后，港股三大指数集体拉升，恒生科技指数一度涨超2%，恒生国企指数、恒生指数跟涨；恒生生物科技指数午后翻红，亚盛医药、翰森制药、科伦博泰生物、先声药业、康方生物等盘中涨幅 ...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261023/c681018111.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261023/c681018111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["03613","IBBQ","BK1161","MEDX","03737","03347","02269","01666","159992","BK1574","06606","06127","02359","06978","02273","01643","03759","09926","LNGR","06160","00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163276368","title":"异动解读｜康方生物盘中下跌3.28%，配售落地后股价继续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1163276368","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163276368?lang=zh_cn&edition=full","pubTime":"2026-10-23 10:00","pubTimestamp":1792720836,"startTime":"0","endTime":"0","summary":"10月23日，康方生物盘中下跌3.28%，报81.15港元，成交额2.51亿港元。近期可对应的公开消息是，公司已完成配售2000万股新股，每股97.76港元，募资净额约19.41亿港元，配售股份占扩大后股本约2.13%。融资落地有助于缓释资金面不确定性，但增发摊薄及配售价之下运行，仍对短线情绪形成压制。公司上半年营收18.06亿元，同比增长27.92%，净亏损4.47亿元，较上年同期收窄；在高研发投入阶段，此次募资主要用于核心管线研发、临床及商业化支持。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康方生物配售落地，股价继续承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677873639","title":"港股通创新药急转直下，发生了什么？520880标的指数跌逾4.6%，再鼎医药、康方生物重挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2677873639","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677873639?lang=zh_cn&edition=full","pubTime":"2026-10-22 11:01","pubTimestamp":1792638060,"startTime":"0","endTime":"0","summary":"10月22日，港股通创新药修复戛然而止，行情急转直下，港股通创新药ETF华宝标的指数下挫逾4.6%，失守所有均线。最新数据显示，截至最新，港股通创新药ETF华宝标的指数市盈率TTM为33.93倍，已回落至近3年39%分位点，配置性价比凸显。低位吸纳港股通创新药核心资产，关注T+0交易工具——港股通创新药ETF华宝：标的指数100%布局创新药研发类公司，近7成仓位押注创新药研发龙头。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-10-22/doc-iniwaezr5258400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0561508036.HKD","BK1574","LU0540923850.HKD","LU2399975544.HKD","LNGR","LU0348735423.USD","LU0348767384.USD","LU0348825331.USD","LU0348766576.USD","LU0634319403.HKD","IE00B543WZ88.USD","LU0348783233.USD","LU0348827113.USD","MEDX","IBBQ","BK4548","LU1961090484.USD","LU2476274308.USD","BK1588","FLHK","IE00B5MMRT66.SGD","LU2778985437.USD","LU0348784397.USD","BK4588","LU1720050803.USD","LU1794554557.SGD","520880","09688","BK1161","BK4531","ZLAB","LU0417516902.SGD","LU2488822045.USD","159992","LU0417516738.SGD","BK4526","BK4139","KURE","LU0417516571.SGD","09926","06978","IE00BPRC5H50.USD","BK4585","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121722934","title":"异动解读｜康方生物盘中下跌3.29%，配售落地后股价回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1121722934","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121722934?lang=zh_cn&edition=full","pubTime":"2026-10-22 09:41","pubTimestamp":1792633300,"startTime":"0","endTime":"0","summary":"10月22日，康方生物盘中下跌3.29%，报89.8港元，成交额1.3亿港元。近端公开消息显示，公司已完成配售2000万股新股，每股97.76港元，募资净额约19.41亿港元，配售股份占扩大后股本约2.13%。融资完成有助于缓释资金面不确定性，但增发带来的摊薄影响仍是市场交易关注点，股价在前期大幅波动后出现回吐。公司上半年营收18.06亿元，同比增长27.92%，净亏损4.47亿元，较上年同期有所收窄。公司仍处于高研发投入阶段，此次募资将主要为核心管线推进提供支持。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康方生物配售落地，股价回吐承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677449556","title":"康方生物累计募资超130亿港元，盈利拐点尚待兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2677449556","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677449556?lang=zh_cn&edition=full","pubTime":"2026-10-21 12:27","pubTimestamp":1792556820,"startTime":"0","endTime":"0","summary":"10月23日至27日，欧洲肿瘤内科学会（ESMO）年会将在马德里举办，这是肿瘤学界一年中规模最大的学术会议，众多管线的最新数据届时将集中发布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610213902470743.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610213902470743.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HELS","LU1961090484.USD","LU0348827113.USD","09926","LU0561508036.HKD","IE00B543WZ88.USD","LU0417516571.SGD","LU0417516902.SGD","LU0348735423.USD","BK1574","LU2476274308.USD","LU0540923850.HKD","LU1794554557.SGD","LU0348825331.USD","LU0348783233.USD","KURE","LU0348767384.USD","BK1161","LU0417516738.SGD","LU1720050803.USD","LU2399975544.HKD","LU2476274720.SGD","LU2488822045.USD","LU2778985437.USD","LU0348766576.USD","LU0634319403.HKD","LU0348784397.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677646635","title":"港股异动 | 创新药股延续涨势 多项重要数据将于ESMO公布 平台型BD接连落地传递信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2677646635","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677646635?lang=zh_cn&edition=full","pubTime":"2026-10-21 10:30","pubTimestamp":1792549810,"startTime":"0","endTime":"0","summary":"国金证券认为，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1720050803.USD","LU0348735423.USD","LU1794554557.SGD","09688","HK0000252160.HKD","BK1588","HK0000500386.USD","06978","LU0417516571.SGD","LU2778985437.USD","HK0000252152.HKD","LU0348766576.USD","IE00B5MMRT66.SGD","LU2399975544.HKD","BK1574","LU2476274720.SGD","LU0417516902.SGD","IBBQ","159992","09926","KCAI","BK1583","LU0348783233.USD","LU0417516738.SGD","IE00B543WZ88.USD","LU2488822045.USD","MEDX","BK4588","09606","LU0634319403.HKD","LU0348767384.USD","LU0348827113.USD","BK1161","LNGR","LU0348784397.USD","VXUS","LU1961090484.USD","LU0540923850.HKD","LU2476274308.USD","LU0348825331.USD","01952","LU2543165471.USD","LU0561508036.HKD","KURE","BK4585","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154333784","title":"异动解读｜康方生物盘中上涨3.88%，配售完成后资金面不确定性阶段缓释","url":"https://stock-news.laohu8.com/highlight/detail?id=1154333784","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154333784?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:34","pubTimestamp":1792546455,"startTime":"0","endTime":"0","summary":"10月21日，康方生物盘中上涨3.88%，报95.7港元，成交额1.11亿港元。近端可对应的公开消息是，公司已完成配售2000万股新股，每股97.76港元，募资净额约19.41亿港元；配售股份占扩大后股本约2.13%，承配人不少于六名。此前市场对折价配售与摊薄较为敏感，完成交割后，融资落地带来的资金面不确定性阶段缓释。公司上半年营收18.06亿元、净亏损4.47亿元，高研发投入背景下，此次补充资金有助于支撑核心管线推进。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康方生物配售完成，资金面压力暂缓","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677643406","title":"【券商聚焦】国金证券：创新药板块迎来业绩兑现与国际化重估共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2677643406","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677643406?lang=zh_cn&edition=full","pubTime":"2026-10-21 09:16","pubTimestamp":1792545406,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国金证券研究指出，创新药前沿技术加速迭代，IO2.0、ADC迭代、自免长效双抗等重塑治疗格局。中国原研资产深度融入全球交易，国际化步入收获期。支付端医保与商保双轮驱动，国谈优化准入，商保目录落地缓解高值药进院约束，本土Biotech净现金流改善、迎来盈亏平衡拐点。海内外政策聚焦真创新，生物类似药温和集采兑现。优质管线梯队完备，百济神州、康方生物、科伦博泰等核心分子加速欧美商业化，创新药板块迎来业绩兑现与国际化重估共振。风险提示：BD受海外地缘政策约束风险；创新药行业竞争加剧风险；医保控费降价不及预期风险；海外流动性收紧风险。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1994055","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","MEDX","09995","LNGR","LU1303224171.USD","LU0823426308.USD","BK1589","LU1807302812.USD","06185","LU0128522744.USD","LU1951186391.HKD","LU0588546209.SGD","02269","LU0456846285.SGD","LU0880133367.SGD","LU0348784397.USD","IE00B0JY6N72.USD","LU0516422366.SGD","LU0320764599.SGD","LU1794554557.SGD","BK1141","KCE","02616","IBBQ","06978","KURE","LU0516422440.USD","LU2097828714.EUR","600109","LU1226288170.HKD","IE0008368742.USD","LU0455707207.USD","LU0417516571.SGD","IE00B031HY20.USD","LU0128526141.USD","BK0183","159992","09926","LU0348783233.USD","IE00BPRC5H50.USD","06160","LU0228659784.USD","BK1574","LU0540923850.HKD","02142","LU1770034418.SGD","09688","01877","01093","01801"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.0835},{"period":"1month","weight":-0.0755},{"period":"3month","weight":-0.0874},{"period":"6month","weight":-0.3737},{"period":"1year","weight":-0.2539},{"period":"ytd","weight":-0.2473}],"compareEarnings":[{"period":"1week","weight":-0.0236},{"period":"1month","weight":-0.0628},{"period":"3month","weight":-0.1069},{"period":"6month","weight":-0.104},{"period":"1year","weight":-0.1234},{"period":"ytd","weight":-0.0989}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼（卡度尼利，PD-1/CTLA-4）、依达方（依沃西，PD-1/VEGF）、莱法利（AK117，CD47）、普络西（AK109，VEGFR-2）、安尼可（派安普利，PD-1）、科泰莱（塔戈利单抗，PD-L1）和用于代谢及自免领域的伊喜宁（伊努西单抗，PCSK9）、爱达罗（依若奇单抗，IL-12/IL-23）、古莫奇单抗（AK111，IL-17）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.021305},{"month":6,"riseRate":0.571429,"avgChangeRate":0.077852},{"month":7,"riseRate":0.571429,"avgChangeRate":0.084887},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.012805},{"month":9,"riseRate":0.571429,"avgChangeRate":0.060911},{"month":10,"riseRate":0.428571,"avgChangeRate":0.008372},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}